Aktuellt
SENASTE
Redeye embraces the positive results from the SOLARIO trial, and we argue that the company has ticked one more box for leading a paradigm shift in its niche. We reiterate our SEK350 base case but, as previously explained, we refrain from making any revisions to our estimates at this point. Still, we feel increasingly confident in our current sales estimates.
LÄS MER
